StockMirror — Stock Screener

POLYMED Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Poly Medicure reported strong Q2/H1 FY27 results with standalone revenue up 17% YoY in Q2 and consolidated revenue up 31% (organic +14%). Gross margin expanded 111 bps YoY to 70.1% standalone, driven by proactive inventory management and price hikes. Management reaffirmed revenue guidance (INR2,300-2,400 cr consolidated) and raised standalone EBITDA margin guidance to 26-27.5%. Key headwinds include West Asia geopolitical issues impacting ROW markets (-7% in Q2), Chinese dumping in dialysis, and PendraCare EBITDA losses due to Middle East exposure. Key tailwinds include Europe recovery (~40% organic growth), India-UK FTA opportunities, DGHS single-use notification, and 30 new product registrations. Capex guidance maintained at INR200-225 cr for FY27.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management reaffirmed revenue guidance while increasing standalone EBITDA margin guidance from 25-27% to 26-27.5%, demonstrating balanced focus. Targeting revenue doubling by FY30 while improving consolidated EBITDA margins.

About Poly Medicure Limited

Poly Medicure Limited (POLYMED) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More